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The parvoviruses are widely spread in many species and are among the smallest DNA animal viruses. The parvovirus is
composed of a single strand molecule of DNA wrapped into an icosahedral capsid. In a viral infection, the massy
capsid participates in the entire viral infection process, which is summarized in this review. The capsid protein VP1 is
primarily responsible for the infectivity of the virus, and the nuclear localization signal (NLS) of the VP1 serves as a
guide to assist the viral genome in locating the nucleus. The dominant protein VP2 provides an “anti-receptor”, which
interacts with the cellular receptor and leads to the further internalization of virus, and, the N-terminal of VP2 also
cooperates with the VP1 to prompt the process of nucleus translocation. Additionally, a cleavage protein VP3 is a part
of the capsid, which exists only in several members of the parvovirus family; however, the function of this cleavage
protein remains to be fully determined. Parvoviruses can suffer from the extreme environmental conditions such as low
pH, or even escape from the recognition of pattern recognition receptors (PRRs), due to the protection of the stable
capsid, which is thought to be an immune escape mechanism. The applications of the capsid proteins to the
screening and the treatment of diseases are also discussed. The processes of viral infection should be noted, because
understanding the virus-host interactions will contribute to the development of therapeutic vaccines.
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Parvoviruses infect a wide range of species, including birds
and mammals. The virus replicates in the nucleus, although
some of the parvoviruses require a helper virus to replicate [1,
2]. The viral replication must occur in mitotic cells because
the virus must use a polymerase to effectively proliferate.
Based on the host specificity, the Parvoviridae family is divided
into two groups, the Parvovirinae and the Densovirinae.
Parvovirinae infects vertebrates, whereas Densovirinae infects
only invertebrates. Recently, a new classification of the Parvo-
viridae family was proposed, and the latest subfamily designa-
tion, the Parvovirinae, now has eight genera: Amdoparvovirus,
Aveparvovirus, Bocaparvovirus, Copiparvovirus, Dependopar-
vovirus, Erythroparvovirus, Protoparvovirus and Tetraparvo-
virus [3]. The human parvovirus B19 (B19) causes a serious
autoimmune disease in children [4]. An infection with the
virus during pregnancy can lead to hydrops foetalis and foetal
loss or congenital infection [5]. The adeno-associated viruses* Correspondence: sophia_cs@163.com; chenganchun@vip.163.com
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the Parvoviridae family, with twelve distinct AAV serotypes
and more than 100 recombinant species [6]. Additionally,
the AAVs cannot effectively complete replication without
the help of viruses such as adenoviruses or herpesviruses
[2]. In animals, the most common symptoms are gastro-
enteritis and diarrhoea [7–9]. In general, parvoviruses ag-
glutinate erythrocytes, but the goose parvovirus (GPV) is
an exception; the GPV cannot agglutinate red blood cells
but agglutinates cattle sperm [8].
Because of the specific immunogenicity, capsid pro-
teins have great potential for the development of
vaccines. The baculovirus expression system has been
widely used to produce virus-like particles (VLPs), which
share a immunogenicity that is similar to native viruses
and that can be applied to further study of the functional
aspects [10, 11]. Generally, the VLPs are well immuno-
gens which can induce a strong and specific antiviral im-
mune response. Although the analyses of the structural
and functional aspects of the VLPs have always attracted
much attention, there is no systematic description of the
function of each capsid protein during the viral invasion.distributed under the terms of the Creative Commons Attribution License
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of parvoviruses and the roles of capsid proteins of the vi-
ruses in viral infection are summarized, leading to
suggestions for possible mechanisms to explain the in-
teractions between virus and host. Moreover, we
reviewed the application of recombinant viral capsids to
the treatment of diseases.
The genome and encoding proteins of parvoviruses
The parvovirus genomes are approximately 5.0 kb in
length and is enclosed within an icosahedron capsid
(T = 1), which is 18–26 nm in diameter. At both ends of
the genome, inverted terminal repeats (ITR) are formed
by palindromic sequences, which are assembled into dif-
ferent shapes of a hairpin structure (depending on virus).
In most of the parvoviruses, the viral DNA encodes two
open reading frames (ORF). The ORF1 encodes non-
structural proteins (NS), and the ORF2 encodes two or
three viral particle (VP) proteins which assemble the
viral capsid; the VP proteins share a common termin-
ation codon. However, a few parvoviruses possess more
than two ORFs, including, for example, members of the
Bocaparvovirus, which have an extra ORF that encodes
a nuclear phosphoprotein NP1 [12–15]. The NS protein
is a replicate protein that control genomic replication, is
cytotoxic to host cells and is a cause of apoptosis [16,
17]. Successful examples of continuously producing viral
particles in cell lines did not occur until a lac repressor-
operator system was included, which first successfully
overcame the cytotoxicity problem and allowed for strin-
gent regulation of these proteins [18]. The NS1 protein
has several replication-related regions, for example, a
DNA-binding region, an ATP binding region, a helicase
domain and a transactivation domain [16]. In the B19,
AAV, minute virus of mice (MVM), canine parvovirus
(CPV), porcine parvovirus (PPV), bovine parvovirus
(BPV) and GPV, the VP1 contains the entire sequence of
the VP2. Compared with the VP2, the VP1 has an extra
length of ~140 amino acids at the N-terminal, with a
phospholipase A2 (PLA2) domain and an NLS. The VP2
constitutes the primary component of the capsid protein
and is highly conserved. The VP3 is a cleavage product
that appears after the translation of VP2, and not all the
parvoviruses have this protein. Although sequence diver-
sity exists among the different species, these viruses have
similar structures as determined by the three-dimensional
structures, such as for B19 [19], AAV [20–27], MVM [28],
CPV [29, 30], BPV [9] and the Aleutian mink disease virus
(ADV) [31].
Role of parvovirus capsid in viral infection
The multifunctional capsid is responsible for the adsorp-
tion on and the entrance into the host cell, intracellular
transport and localization, viral egress and induction ofthe immune response. Figure 1 shows the process of
viral infection. In the following sections, the function of
each capsid protein during the viral infection will be
discussed.
VP1 is responsible for viral infectivity
In most parvoviruses, the VP1 N-terminal changes loca-
tion from internal to being external of the capsid when
exposed to some extreme chemical and physical condi-
tions, such as heat or low pH. Moreover, the heat-induced
exposure of the VP1 N-terminal is an irreversible process
[32, 33]. The conformational changes of the capsid VP1
and the exposure of the VP1 N-terminal play a consider-
able role in viral infection. In previous studies with B19, a
recombinant capsid VP1 N-terminal with a unique region
(VP1u) was readily recognized by a specific monoclonal
antibody, whereas the natural capsid was not recognized.
Furthermore, after a heat or a low-pH treatment, the na-
tive VP1u was accessible to the antibody [34]. These re-
sults revealed a primarily conformational difference
between the native and recombinant virion for VP1u and
preliminarily showed that the B19 VP1u peptides were
originally located inside the capsid. Additionally, the CPV
and MVM virions exposed the VP1 N-terminal during
endosomal trafficking, which also argued that the VP1 N-
terminal was initially hidden in the viral capsid [33, 35].
Mutational experiments confirmed that the VP1 N-
terminal of the MVM directly affected the infectivity of
the virus [36]. Additionally, the direct effect the VP1 N-
terminal on infectivity was observed with AAV-2. The
microinjection of wild-type AAV-2 directly into the cyto-
plasm resulted in low infectivity, but the infectivity im-
proved with the exposure of the VP1 N-terminal, which
strongly suggested again that the VP1 N-termini are es-
sential for the intracellular virion to initiate infection [37].
Additional studies revealed that B19 VP1u became exter-
nal after primary cellular receptor attachment [38, 39].
Furthermore, the VP1u mediated internalization was a
highly restricted process and only occurred in the permis-
sive erythroid lineages, which suggested a viral tropism
and pathogenesis [40].
The NLS is a nuclear localization signal that assists in
the navigation of viruses to the nucleus, which leads to
further nuclear translocation. A previous study identified
a typical NLS on the VP1 N-terminal residues 4–13 in
the CPV and demonstrated that the nuclear transloca-
tion was an ATP-dependent process [41]. An NLS was
also identified in the MVM [36]. Moreover, the VP1 N-
terminal region of the MVM is composed of four basic
amino acid clusters, BC1, BC2, BC3 and BC4. Muta-
tional and biochemical studies determined that BC1 and
BC2 exhibited a great potential for nuclear transport
[36]. The sequences of the BCs are highly conserved
among parvoviruses; thus, we inferred that the BC
Fig. 1 A schematic of the parvovirus infection process, mediated by the Clathrin-dependent endocytic pathway. The internalization of the virus is
mediated by the endocytosis pathway, primarily through the following steps. a Receptor binding-mediated internalization. The cellular receptor for
parvovirus B19 is globoside, the cellular receptor for CPV is transferrin receptor (TfR), and the cellular receptor for MVM and BPV is sialic acid. b Form of
the early endosome (pH 6.0-6.5). c Transformed into the late endosome at lower pH conditions (pH 5). d Transformed into the lysosome and
the activation of phospholipase A2 (PLA2) (pH 4.0). e The activated PLA2 destroys the integrity of the lysosomal membrane. Thus, the viruses
are released into the cytosol. f The viruses are transported towards the nucleus and target on the karyotheca with the help of the VP1 nuclear
localization signal (NLS). The movement of microtubule and actin filaments are involved in the entire process of viral infection, from the early
endosome to the peripheral nucleus. The viral genome begins to replicate and assemble after trafficking through the nuclear pore complex
(NPC). The matured virions finally move through the NPC and are released extracellular
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in the nuclear transport in other representative parvovi-
ruses, as well. A recent study showed that the PPV was
distinctly different from the closely related parvoviruses
because the PPV had more than one activated NLS, in-
cluding a novel nuclear localization motif (NLM) [42].
One of the NLSs is typically located on the VP1 N-
terminal and plays a role in the early steps of infection,
whereas the other NLS is a novel NLM that targets the
VP2 trimers to the nucleus late in the infection [42].
Additionally, in the genus Bocaparvovirus, the NLSs dis-
play some distinct properties in comparison with the
other parvoviruses. Direct experiments suggest that the
human bocavirus NP1 protein possesses a nonconven-
tional NLS and is capable of transporting β-galactosidase
fusion proteins to the nucleus [43], which indicates that
the NP1 plays a role in nuclear translocation. Notably, in
ADV, the VP1 binds the DNA, and the virus can not
replicate efficiently in the nucleus because of the absence
of the NLS [44].
In the majority of parvoviruses, the VP1 N-termini
have a secretory PLA2 (sPLA2s) homology domain,which contains the catalytic site of a sPLA2 and a con-
served Ca2+ binding loop. However, a few of the viruses
do not have this motif. The PLA2 is a lipolytic enzyme
that destroys the membrane and allows the viruses to es-
cape from the lysosome. Additionally, the PLA2 is lo-
cated initially within the native capsid but is then turned
to the outside after heat or pH treatments [34]. In
addition to the conserved amino acids within the VP1u
PLA2 motif, some nonconserved amino acid residues
around the VP1u also have an effect on PLA2 activity.
The B19 mutants of the PLA2 motif showed a significant
decrease in PLA2 activity and viral infectivity, which sug-
gested that the PLA2 played an important role in the
B19 life cycle [45]. Furthermore, in their study, Deng et al.
demonstrated that the integrity of the cell membrane was
destroyed by PLA2 in a B19 infection. When the UT7-Epo
cells were incubated with purified VP1u proteins, the cell
morphology changed with time until finally the change
was abrupt, resulting even in death, with an increase in
the VP1u treatment. However, in comparison, the cells
with mutant VP1u proteins or those in the control treat-
ment did not change [46]. The identical effect was also
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and conformational changes that occurred during the VP1
N-terminal externalization from the inner capsid to the
outside were physically revealed [48]. In a comparison
with humans, the question remains whether the same
process occurs in animals. In the MVM, the phosphoryl-
ation of PLA2 activity also influenced the stage of virus re-
leased from the endosome. After A9 cells were transfected
with VP1u mutant infectious clones, the PLA2 activity and
the MVM infectivity were both abrogated [49]. Similarly
in CPVs, when the capsid was incubated with PLA2 inhibi-
tors, the infectivity of the CPVs was significantly reduced
and the endosome membrane permeability was changed
during the period of CPV infection [35]. These results also
demonstrated that PLA2 activity is essential for effective
infection.
VP2 participates in the receptor recognition and in
nuclear translocation
Viral infection begins with the adhesion of the virus to a
cell surface receptor [50]. In viruses, there is also an
“anti-receptor” that is found in the parvovirus VP2 pro-
tein, which attaches to the cell receptor and begins in-
ternalization (Table 1). With the use of the cryo-electron
microscopy technique at the resolution of 8-Å, a depres-
sion at the icosahedral threefold axes of the B19 VP2
capsid was found, which bound to the cellular receptor
globoside [51]. In the AAV-2, the heparin sulphate pro-
teoglycan is a dominant receptor [52], which shares a
common receptor α5β1 with B19. When the AAV-2 was
combined with heparin, at ~18 Å resolution under cryo-
electron microscopy, the conformational changes of the
capsid were revealed; the tip of the protrusions on the
three-fold axes became flat, and the top of the channel
located on top of the five-fold axes grew broader [53]. In
contrast to B19, there is a distinct “spike” on the three-
fold axes of CPV VP2, based on observations of the 3D
structure. On the VP2 capsid surface, there is a putative
receptor-binding region located in a depression with a
canyon-like shape. Moreover, one of the binding regions
is located between the two icosahedral three-fold axes,
and the other binding region is on the five-fold axes
[30]. The BPV capsid VP2 showed a common parvovirus
feature, obvious protrusions encircling the threefold
axes, which indicated a potential site for receptor recog-
nition [9]. For ADV, the 3D structure of VP2 capsid have
been determined to 22 Å resolution, a dimple at the
twofold axes was indicated to be involed in the recogni-
tion of cellular receptor [31].
Notably, a new NLS of the B19 virus was located on
the VP2 N-terminal, which could facilitate nuclear trans-
port [54]. In the case of MVM, the VP2 N-terminal also
acted as a nuclear export signal (NES) [55]. In further
studies, when the temperature reached a specific level,the VP2 N-terminal region of the MVM transferred
from the inner capsid through the five-fold axes to the
outside of the virion [56]. After a series of conform-
ational changes and the exposure of the NLS and NLM,
the VP1 cooperated with the VP2 and formed a trimer
with the assistance of VP2-chaperone activity to finally
traffic through the nuclear pore complex [57]. Addition-
ally, the VP2 N-terminal was phosphorylated during the
late stage of the MVM life cycle, and therefore, the vi-
ruses spread to neighbouring cells efficiently prompted
by the activated VP2. Miller et al. hypothesised that the
N-terminal of the VP2 together with the NS2 had an in-
fluence on the viral egress from the nucleus [58]. In the
case of ADV, a D534 residue of the VP2 enabled the
ADV-G to replicate in mink, which induced a continu-
ous immune response [59].
VP3 function as a capsid scaffold?
The VP3 generally occurs only when the viral genome
has completed the capsid assembly and packaging. In
the MVM, the VP3 is generated from the cleavage of
VP2 at approximately 25 amino acids from the N-
terminal. A trypsin digestion experiment demonstrated
that this proteolytic reaction occurred only in the ma-
ture virion, with an intact genome. Although the VP1
has an identical proteolytic site, cleavage does not occur
[60]. An identical proteolytic phenomenon also appeared
in the ADV, but with some dissimilarity. Previous studies
showed that during an ADV infection or when the viral
capsid only was expressed an extra, an unknown 26 kDa
protein was produced, which was recently identified as a
split product of the capsid VP1 and VP2. Based on the
results, the caspase family was activated during the ex-
pression of the ADV capsid proteins, and the caspase-7
response was to specifically cleavage the capsid at a dis-
tinct site [61].
The studies on VP1 and VP2 are sufficiently compre-
hensive, but research on VP3 is lacking, and further
studies are required to reveal the discrete functions of
this protein. For birds, the VP3 is a prominent protein in
both GPV and Muscovy duck parvovirus (MDPV), in
which the VP3 induced a distinct immune response [62].
Recombinant GPV capsid proteins were expressed and
purified to apply to an in vivo assay, and all of the VLPs
induced a strong immune response in the susceptible
geese, whereas the VLPs-VP2 and VLPs-VP3 induced
higher concentrations of neutralized antibodies than the
VLPs-VP1 [11].
Notably, a 23 kDa protein encoded by the AAV ORF2
promoted the assembly of the VP3 capsid and was
named as one of the assembly-activating proteins (AAP).
When the AAP was expressed, some of the VP3 was
transformed into the nucleus to form the capsid [63],
which indicated that the AAP enabled the transport of
Table 1 The subfamily Parvovirinae: the interaction between the virus and the host
Genus Virus Host Cellular Receptor Invasion pathway Binding site Accession
number
Amdoparvovirus Aleutian mink disease
virus
Mink Sialic acid - A protrusions on threefold axes and
the wall of the dimples on twofold axe
M20036
Bocaparvovirus Bovine parvovirus Bovine α2-3 O-linked sialic acid Clathrin-dependent endocytic pathway - M14363
Dependoparvovirus Adeno-associated
virus
Human Heparan sufate proteoglycan,
sialic acid, aVβ5 integrin
Clathrin-dependent or independent
internalization
-
Goose parvovirus Goose, Muscovy
duck
- - - U25749
Erythroparvovirus Human parvovirus
B19
Human P antigen, α5β1, ku80 Clathrin-dependent endocytic pathway At depression of the three fold axis NC_000883
Protoparvovirus Canine parvovirus Dogs, cats Transferrin receptor Clathrin-dependent endocytic pathway A distinct “spike” on threefold axes EF011664
Minute virus of mice Rodents α2-3 and α2-8 N-linked
Sialic acid
Both clathrin- and lipid-raft mediated
endocytosis
At the depression of twofold axes and
the floor of twofold axes depression
V01115
Porcine parvovirus Swine α2-3 N- and O-linked
Sialic Acid
Macropinocytosis and Clathrin-dependent
endocytic pathway
- M38367
Mink enteritis virus Mink Transferrin receptor - - D00765
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capsid package. The inference was that the VP3 was re-
sponsible for the capsid assembly and the virion stability.
However, the role of VP3 in the parvovirus life cycle re-
mains to be fully understood.
Applications of capsid proteins
For the viral capsid, engineers conducted a variety of in-
novations. Other viruses, for example, a non-enveloped
virus in the Picornavirus family that causes foot-and-
mouth disease (FMD), have much in common with par-
voviruses, and interference against the VP1 structural
protein successfully produced a protective effect in both
cells and suckling mice [64]. This result indicated that
RNAi technology might provide a therapeutic measure
to treat virus infection. In the parvoviruses, the domin-
ant antigenic determinants are located on the capsid.
Langeveld et al. used an immunofluorescent assay to
analyse the B-cell epitopes on structural proteins and,
based on this research, obtained the CPV polypeptide
vaccine [65]. Moreover, the VLPs-VP2 of the CPV
expressed in Escherichia coli and inoculated in mice
showed subtle differences between the native viruses and
the VLPs in neutralizing antibody titres, in addition to
the immune response of the T-cells [66]. The CPV VLPs
shared properties closely with the native virus and could
be profitable candidates for therapeutic vaccines. Fur-
thermore, researchers used the relation between CPV
and its cellular receptor TfR (also exist in human cells) to
explore a potential nano-container for tumor targeting. In
their study, the accessible lysines on the viral capsid were
derivatized with dye molecules. After incubation with TfR
expression or those that lacked the TfR expression cell
lines, Researchers found that the internalization of the la-
belled CPV-VLPs was observed only in the TfR expression
cell lines [67], which indicated that the CPV-VLPs could
act as a target delivery substance.
Adeno-associated viruses (AAVs) are nonpathogenic
members of the Parvoviridae family. The last 10 years
has witnessed a surge of studies on the use of AAVs as
vectors. For example, a recombinant triple-tyrosine mu-
tant AAV-2 vector significantly increased the efficiency
of gene transduction, approximately three-fold com-
pared with the wild type [68]. Thus, we could minimize
the therapeutic dose and produce a preferred level of
protection. More recently, Giridhara et al. found that
AAV vectors activated the NF-κB pathway, which sug-
gested an application in gene therapy [69]. Furthermore,
Mirta et al. constructed a recombinant AAV capsid vec-
tor, which contained a fragment of a tumour-targeting
sequence, and the modified mutant resulted in high
transduction in tumour cells, but the transduction in
293 T cells was poorly induced. By contrast, the native
AAV capsid was highly expressed in the 293 T cell lines,and this altered tropism suggested a strategy to develop
an in vivo-targeted vaccine [70].
Conclusions
Although the size and structure of the parvovirus capsid
are simple, each component of the capsid performs a
vital function in the life cycle of a virus. The compo-
nents of the capsid participate in cellular recognition,
the endosomal pathway and nuclear trafficking and even
induce the immune response. In this review, we summa-
rized the roles of the capsid in viral infection and also
the potential applications of recombinant viral capsids in
the treatment of disease. In the last several years, studies
on the capsids of the parvoviruses have grown in num-
ber. Nevertheless, the exact function of the VP3 must be
fully elucidated. Recently, many new virus strains were
categorized into Parvoviridae after the revision of the
family; however, the studies on these strains remain at
the bioinformatics analysis stage. In the future, more
functional-type research must be developed. Further-
more, the study of virus-host interactions remains a
major challenge, and an understanding of the mecha-
nisms of the interplay between the virus and the host
will contribute to the development of future treatments.
Additionally, the safety of the engineered vaccines re-
quires consideration.
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